Post hoc analysis of a placebo-controlled trial in 383 patients with MDD or bipolar disorder and a depressive episode with mixed features: lumateperone 42 mg improved 9 of 10 MADRS items versus placebo at day 43; suicidal thoughts did not improve.
Secondary analysisn = 383
Yatham et al. The efficacy of lumateperone across symptoms of a major depressive episode with mixed features in patients with major depressive disorder and bipolar disorder: Post hoc analyses